Good day, and welcome to the Lifeward Inc fourth quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to withdraw your question, please press star then two. Please note today's event is being recorded. I would now like to turn the conference over to Almog Adar, Chief Financial Officer. Please go ahead. Thank you, Rocco, and thanks, everyone who's joined us on the call today. My name is Almog Adar. I'm Lifeward's Chief Financial Officer, and with me on today's call is our President and Chief Executive Officer, Mark Grant. Earlier this morning, Lifeward issued a press release detailing the financial results for the fourth quarter and the full year ended December 31st, 2025. I would ask you to review the full text of our forward-looking statements from the press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filing with the SEC. With that, I will turn the call over to Mark. Good morning, and thanks, everyone, for joining us on the call today. Before we get into the details of the quarter and the year, I want to start with what we believe is fundamental to the Lifeward investment thesis today. We're executing against a strategy to build a leading diversified biomedical innovation company with multiple technology platforms and strong clinical foundations. Importantly, we're establishing a clear line of sight to scale through continued progress in reimbursement, commercial execution, and product innovation. Our strategic transaction with Oramed gives us meaningful access to capital to support our growth initiatives, and we remain focused on driving the business toward cash flow positive operations while investing in innovations that will define the future of the company. An important milestone for Lifeward is the pending close of our strategic agreement with Oramed following the receipt of shareholder approval last week. This partnership significantly strengthens our financial foundation and expands our strategic scope. I want to thank our shareholders for approving the transaction. Your support reflects confidence in the strategy we've laid out and the opportunity ahead of us. I also want to acknowledge the outstanding team at Oramed. They've been great partners, and I look forward to building a long-term collaboration that creates meaningful value for patients, partners, and shareholders. Personally, this opportunity is particularly exciting for me given my background in diabetes at Medtronic and metabolic health at Bristol Myers Squibb. One of the more compelling assets in this partnership is ORMD-0801, an advanced clinical stage oral insulin candidate that has the potential to fundamentally change how insulin therapy is delivered. Because oral insulin is delivered through the gut, it goes through the liver first, mimicking the path of natural insulin for the pancreas. For the patient, this can mean better regulation of glucose production by the liver and less circulating through the body, which can reduce weight gain and the risk of hypoglycemia. Multiple studies have shown no increased risk of hypoglycemia compared with placebo. This is an important distinction in the insulin field and, if successfully developed, could meaningfully improve both patient safety and treatment adherence. We're excited about the potential of this program and believe it represents meaningful addition to Lifeward's long-term innovation platform. The current plan is to move forward with the new U.S. study. The unique funding structure for the clinical program also allows Lifeward to maintain pinpoint operational focus on profitability and cash generation of our portfolio while simultaneously gaining exposure to the potential substantial upside of a large-scale biotech opportunity. Another major recent step forward for the company is the acquisition of intellectual property and technology from Skelable. This transaction was structured in a very capital efficient way, and we believe it will prove to be highly accretive as the technology advances to market. The technology we acquired supports development of a powered upper extremity orthotic system with AI capabilities designed to assist functional movement and restore function in individuals with weakened or paralyzed arms and hands, particularly following stroke. The device is intended to enable patients to perform activities of daily living that would otherwise be very difficult or impossible while supporting therapeutic goals such as muscle re-education and improved range of motion. In the U.S. alone, this upper body neuro rehab system can help an estimated 245,000 newly diagnosed stroke survivors annually and an addition of 4.6 million stroke survivors who remain disabled. With plans to develop and launch the product, we are eager to get to this patient population. What makes this acquisition particularly valuable is not only the technology itself, but it's the team that comes with it. As you know, you don't have the opportunity for outside in inflection points that often. The core Skelable engineering group will be joining Lifeward, bringing more than 60 years of combined experience across electrical, software, mechanical, and industrial design. That experience is incredibly important as we integrate the technology into our development framework. Bringing the original engineering team with the platform ensures continuity of knowledge and allows for a disciplined transfer of intellectual property, design intent, and technical architecture into our broader pipeline. The stellar engineering team will also be a core team working on advancing and the rest of our neuro rehab product portfolio. We believe this platform expands Lifeward's leadership into whole body robotic rehabilitation and opens a significant market opportunity with neuro rehabilitation. In fact, the new platform is highly complementary to our existing ReWalk ecosystem. We will leverage our established clinical relationships, distribution network, and reimbursement channels to accelerate at time of commercialization. I want to underscore here that Lifeward's focus in robotic rehabilitative technologies is exactly that, to rehabilitate and help the human return to full function or return to as much function as humanly possible. We're committed to continuous innovation, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. Now turning to our established core neuro rehab business. We continued to make important progress across reimbursement, clinical partnerships, and global distribution during the year. At the same time, revenue for the quarter and for the full year came in lower than estimated, and there were two primary drivers behind that. First, in the United States, we implemented a major change in our sales and distribution infrastructure. As we discussed on our third quarter call, we began a transition toward a hybrid model that combines our internal direct sales efforts with external channel partnerships. Building those partnerships takes time. They don't translate into revenue overnight, so you're not seeing the full impact of those changes in our numbers yet. Within this restructured, also our sales organization internally to better align with our business evolving. Today, our commercial efforts operate across three focus areas. First, our direct-to-patient channel, which supports individuals pursuing a personal ReWalk system through the reimbursement process. Second, our capital equipment sales team, which focuses on institutional customers, including rehabilitation centers, hospitals, and sports medicine facilities for AlterG. We believe there are substantial untapped opportunities here that can better be served by our capital equipment sales team. The third is a dedicated reimbursement and payer engagement function that works across all payers to expand coverage and support both our direct and distribution channels. As you know, reimbursement is a critical driver of our long-term growth strategy, and building a stronger payer engagement capability is essential to expanding patient access, accelerating adoption of our technologies. It's critical for our patients to be able to access our technologies through their healthcare benefit in their community. We believe this structure will ultimately improve the overall sales process, strengthen payer engagement, and drive greater adoption. As those changes mature, we expect to see the positive effects begin to show in the coming quarters. The second factor affecting the revenue was a decline in AlterG sales tied to a specific distributor dynamic. In 2024, one of our distributors made a very large inventory purchase. That distributor did not place that comparable in 2025, which created a year-over-year comparison headwind. Based on our discussions with them, we expect that purchasing to normalize again in 2026. Despite those temporary dynamics, the underlying fundamentals of the business remain strong. Reimbursement coverage continues to expand, clinical demand remains solid, and we're building a growing backlog and qualified pipeline. Recently, we achieved reimbursement for coverage of ReWalk in the three largest Medicare Advantage insurers in the U.S., Aetna, Humana, and UnitedHealthcare, which collectively represent over 16 million covered lives in America. We also made meaningful progress expanding international distribution for ReWalk. Following the receipt of the CE mark in September of last year, we have been accelerating our efforts across Europe. Germany has become our primary international test market and is proving to be valuable insights into reimbursement pathways, clinical adoption, and patient demand. International markets represent a significant long-term opportunity for the ReWalk platform, and we're opportunistic about the trajectory we're seeing so far. Through an agreement with Verita Neuro and a partner-led capital-efficient structure, we expanded distribution into Mexico, Thailand, and the United Arab Emirates. Our core neuro rehabilitation business serves as a powerful innovation engine for Lifeward. We have multiple next-generation technologies in development. A new version of AlterG should be expected, and our next generation ReWalk is currently targeted, and with the Skelable IP and technology acquisition, we expect our upper body exoskeleton platform to reach the market too. Together, these programs significantly expand our addressable market and strengthen our long-term product pipeline. I will now turn the call over to Almog to review our financial results and provide additional detail in operating performance and liquidity position. Before doing that, please note, given the significant transformation Lifeward has recently undergone and the pending close of our agreement with Oramed, we will not be providing guidance at this time. We remain excited about the long-term prospects and cautiously optimistic about the growth in our core med tech business, together with continued improvements in operating expenses, will help drive the company toward a positive cash flow in the near future. Thank you, Mark. Today, as we have a lot to share about the existing transition Lifeward is making into a diversified biomedical company, I will review highlights of our full year 2025 results. You may refer to the detailed report for the quarter and full year in our press release, which was issued earlier today. Please keep in mind that as we review our results, I will discuss both GAAP and non-GAAP figures. The non-GAAP results exclude the item detailed in the reconciliation table in today's earnings release and, in our view, provide a clear picture of the company's underlying operating performance. I encourage you to refer to the GAAP results in the reconciliation table as we go through the 2025 financials. Revenue for the year ended December 31st, 2025, was $22 million compared to $25.7 million in 2024, a decrease of approximately 14%. Revenue from the sales of ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024. Importantly, while revenue remained relatively stable, the number of units sold increased by 22% year-over-year, reflecting growing adoption of the ReWalk Personal System and increased reimbursement-driven demand. We believe this trend reflects continued progress in reimbursement coverage and increasing clinical adoption of the ReWalk Personal System. Revenue of the MyoCycle FES bike declined by 50% to $600,000, primarily reflecting the transition away from an exclusive distribution arrangement and the company's strategic focus on its core product portfolio. Revenue from the sales of AlterG products and services was $12.9 million, a decline of 18% from 2024. This decrease was primarily due to lower international sales, including timing factor related to one international distributor that had placed larger orders in the fourth quarter of 2024. We believe the decline largely reflects the timing of distributor orders, which can vary from period to period. Across both the ReWalk and AlterG product lines, our commercial pipeline remains healthy. For the ReWalk product line, we closed the year with a pipeline of more than 104 qualified leads in process in the United States. Our growing medical leg-related accounts receivable balance also positions us well for future cash inflows. In Germany, we had 49 leads in process at year-end, including 22 active rentals which historically convert to sales within three to six months. For AlterG, we closed the quarter with 26 systems in backlog. Move to gross profit. Gross profit increased in 2025 to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024. On a non-GAAP basis, 2025 gross profit was $9 million or 41% of revenue, compared to $11 million or 43% of revenue in 2024. The year-over-year decrease in adjusted gross margin was primarily driven by lower sales volume, which reduced absorption of fixed manufacturing overhead as well as higher tariffs and freight expenses. Operating expenses declined by 25% to $28.1 million in 2025 compared to $37.6 million in 2024. This decrease primarily reflects the impact of larger impairment charge recognized in the fourth quarter of 2024 related to certain acquired intangible assets, compared to a $2.8 million goodwill impairment charge recorded in 2025. On a non-GAAP basis, adjusted operating expenses also declined by 12% to $24.1 million in 2025 compared to $27.5 million in 2024. This decrease was primarily driven by improved productivity in marketing and sales operations, greater efficiency in reimbursement activities, and lower R&D spending following the completion of major development programs. We expect the positive trend in marketing and sales efficiencies to continue into 2026. At the same time, we plan to increase investment in R&D as we advance new products to market, including our recently acquired power upper body exoskeleton. Operating loss narrowed by 33% in 2025 to $19.7 million compared to $29.3 million in 2024. This was primarily due to a $9.8 million impairment charge recognized in the fourth quarter of 2024. On a non-GAAP basis, operating loss narrowed by 9% to $15.1 million compared to $16.6 million in 2024. Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024. On a non-GAAP basis, adjusted net loss narrowed by 5% to $15.3 million in 2025 compared to $16.2 million in the prior years. We also reduced operating cash usage by 23% to $16.8 million in 2025 compared to $21.7 million in 2024. The improvement was primarily driven by better working capital management, including stronger collection of receivables and lower inventory levels. The benefits was partially offset by lower revenues relative to operating expenses. During the fourth quarter, we entered into a $3 million loan agreement with Oramed, providing additional capital support to further strengthen our liquidity position as we move towards closing the broader strategic transaction. As of December 31, 2025, Lifeward had $2.2 million in unrestricted cash and cash equivalents on its balance sheet. We expect to finalize the closing of our strategic transaction with Oramed in the coming days, with only a few remaining administrative steps. Upon closing of the transaction, the company expects to receive $10 million in a convertible note, a financing from Oramed and another investor, as described in January 13th, 2026, press release. With that, I will turn the call back to Mark for closing remarks. To close, I want to return to the broader picture. Lifeward today is evolving into a diversified biomedical innovation company built on multiple complementary platforms, neurorehabilitation, robotics, and metabolic therapeutics. Each of these areas offers meaningful growth potential, and together they position us to build a company with scale and impact of a billion-dollar-plus enterprise over time. With Oramed partnership, we now have access to the funding necessary to execute this strategy, and we will remain disciplined in our approach as we move the company forward to cash flow positive operations. We're confident in our roadmap, confident in the strength of our technology platforms, and confident in our ability to execute. Thank you, everyone. Thank you. We'll now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If your question has already been addressed and you'd like to remove yourself from queue, please press star then two. Our first question today comes from Yi- Jen at Ladenburg Thalmann. Please go ahead. Good morning, and thanks for taking questions and congrats on the transformation. Maybe a few questions related to that. The first one is for the Oramed POD technology. I mean, if the focus is on this oral insulin, how would that align with your? I mean, first of all, how much work is needed to be done before get approved? And secondly, how would that align with your or leverage your commercial infrastructure? Yeah, a lot of that question is gonna have to be answered once we actually get through the close. In short, right, you know, I've got a long history, almost three decades in the metabolic space, and so this is really drive synergies across med tech and biotech. You know, when you're looking at a diversified portfolio and a durable company, I think it positions us really well. I also think that if you look at how we're approaching the market and moving from a centralized approach of selling patient to patient to decentralized and excluding commercial models, you know, having a biotechnology like this fits. You know, we become an innovation company that then allows us to actually move into a decentralized approach. Okay. Maybe just if I may add it. In terms of your current commercial infrastructure, how would the end product like that be able to leverage your current, you know, availability, or you would need to build up a new sales force or other to be able to accomplish successful commercialization? Yeah. I think the beauty of this is in the short term. You know, while we continue to go through clinical trials, this is completely funded through the acquisition and allows us to actually keep completely focused on our core business while we continue to expand the opportunity with Oramed. The good news is, you know, in the short- Okay. Yeah. Good news is, Yale, in the short term, it's actually fully funded and in motion. Secondarily, you know, just to expand on your question of, you know, what does it mean for our distribution network? Look, I've got multiple years experience developing these networks and bringing products to market. When the commercialization opportunity presents itself, we'll be adept at that as a company. It's something I'm going to pull through while we're going through the clinical trials. Maybe just one more question here. In terms of your upper extremity robotic assistance, I guess you suggest that it will take 18-24 months to complete. Could you give us a little bit specific timeline in terms of the study need to be done, the regulatory process and maybe lastly, how do you see the market of that and how that complements your ReWalk system? Thanks. Yeah. If we're able to stay in the current space that we believe we're going to be in in coding, this becomes a 510(k)-exempt product. As we go through innovation and bringing it to commercialization, the barriers to entry are quite low. We still have more to discover as we go through and making sure we meet the appropriate coding and making sure that we fall into that category. That's the trajectory that we believe that we see and that we've discovered during diligence. As far as the 18-24 months, we're confident hitting that. We've already started that work. Would that be some sort of clinical study needed there? Any timeline you can suggest on that as well as the timeline after that for the regulatory process. Thanks. We haven't outlined the exact clinical study yet. What we do know is it won't need to be high in numbers, and it's probably gonna be more oriented to a safety or bench study, to show efficacy and safety. It's not something that takes a large amount of time, given the barrier, given the hurdles to entry are low. You don't have to have a high clinical bar. Okay, maybe the last question here is in terms of this, the upper extremity, there seems to be other competitor in this space, currently, and how do you see your benefits over, you know, others to be, you know, commercially successful? And thanks. Look, that's a great question. Yeah, I think that there's so much to come that I'm gonna reserve the opportunity to answer that at a later date. As I see it today, we're gonna enter the market differently. While there may be competitors in this space, our job is actually for expansion into new areas. Let me get a little bit under my belt before I actually address that one. I think you guys are gonna be excited about the simplicity and efficacy of this product. Okay, great. Appreciate it. Thanks a lot. Congrats on the transformation process, and I get back to the queue. Yeah, thank you. Thank you. As a reminder to ask a question, please press star then one. Our next question comes from Swayampakula Ramakanth with H.C. Wainwright & Co. Please go ahead. Thank you. Thank you. This is RK from H.C. Wainwright. Good morning, Mark and Almog. A broad high-level question, you know, similar to what Yale was just asking. I think about two or almost three years ago now, the previous management brought in AlterG to kind of expand on their, you know, within the med tech mobility space. And then, you know, it just, you know, trying to integrate that whole business together when Mark, you came on board, and now you're kind of pulling another lever into, kind of biotech sort of space. Plus on top of that, you added this upper extremity portion of it. In general, you know, for an investor trying to follow the story, how should he or she think about this, you know, at a high level? You know, if they are concerned that you're going multiple places without kind of strengthening or deepening in one area, you know, is that a fair assessment or people are not really understanding, you know, the strategy? RK, great to hear your voice, and thank you for the question. Look, I think the fundamentals of commercialization, you know, weren't as strong or stable as they should have been. I think what everybody should expect is getting products to the market through the right channel with the right coverage are most important. What you're gonna see over time is us evolving into an innovation company that understands the channels to go to market. It's not gonna matter whether it's a biotech or a med tech product. I'm gonna use the experience that I've gained over the last 30 years and also the experience that we're building within the organization through our payer and channel team to exploit these opportunities. I think the expectation is, hey, listen, you've got a very diversified med tech and biotech portfolio, which should be very, gosh, exciting, durable. It should be able to weather the storms of what comes and goes for us. Also give us a lot of different opportunities to move products into the space. What you're gonna see is this will become an execution company that understands reimbursement and commercialization better than anybody else. As you know, but I'll make sure the broader audience does, I've actually authored thousands of payer and commercial contracts across the globe. Bringing that discipline here into the business coupled with the new operational discipline, that's what we should be known for. You know, is getting the right products through the right channels at the right time with the operational discipline that allows us to scale. Okay. I think, you know, the one thing that's probably a little confusing to everybody, so I'll get the elephant in the room. You know, being a core neuro med tech company and then moving into biologics, you know, does it make sense? From an investor standpoint, it absolutely makes sense. Who wouldn't want the aspects of having a biologic on the hook, you know, inside the organization? Who also wouldn't wanna have it on the hook for somebody who's known for executional discipline and commercial channels? You know, I think that, you know, I'm gonna have to work over time on my talk track around what it looks like when you have multiple backgrounds. If you look across, you know, some of the larger organizations in the world, having a biodiverse med tech company is important, and having those differentials in the same ecosystem is doable. Okay. Thanks for that. Talking about execution, you know, initially we were under the impression that, you know, your full year revenues would be within the range of $24 million-$26 million, but obviously it's higher. What drove this additional execution? And do you think, you know, some of the things that you brought to the table are helping out, and that's the sort of stuff that we should be looking for in 2026 and 2027? I'm gonna describe this company a little bit because I think it's important to the answer. You know, I view the company as a startup even though it's actually got a long tenured history. The reason I do that is because the commercialization and understanding of the reimbursement pathways weren't explicit. As we've integrated those into the organization and started to pave the way for growing the reimbursement, which everybody has seen, you know, since I've joined, we've started to garner better payer and global coverage, and we'll continue to do that over time. We're still not there, right? We still have another 12-18 months until we maximize the coverage across our products. I think that's important. That discipline did not exist. Secondarily, there was a lot of lift and shift of manufacturing that was going on as I entered the business. I would love to tell you it was as planful as it should have been, and it wasn't. The good news is I've done it before, so we actually have cleaned up some of those areas. We're looking for the highest quality products on the market, you know, delivered on time. And we've gone through those disciplined executions inside the company and started to put the framework so we can lift and shift and do this with other products. I think really the importance of building the business fundamentally, and I've said this before from a foundation from the bottom up, you know, the good news is there wasn't a lot here. When we actually, you know, I know what good looks like, so when we build it from the bottom up, we'll have the operational procedures in place to bring in new technologies. We'll also have the reimbursement understanding and a team that's well adept across a multitude of products, whether it's biotech or medtech. Then lastly, we'll have the channels for distribution already set up and going. Those three areas are core to us as we go forward. Okay. One last question from me before I get back onto the queue. You know, in terms of placements for Medicare beneficiaries this year, obviously it was a record. You know, is there a way for you to quantify the backlog that you currently have as you enter 2026? RK, there is, you guys know that we've been getting to the data. As we've expanded our payer coverage, though, we're going back through the qualified leads and pulling more and more into the pipeline. That's new since we've got a lot of reimbursement coverage. I think what's exciting is the 22% growth in units year-over-year. I think you need to stay hyper-focused on that and hold us to that unit number. You're going to see that expand as we move, you know, through this quarter and into next. The pipeline is not solidified right now because the reimbursement is growing. The line of sight is actually growing, which is good news, but I don't have the exact numbers for you today. Okay. Thank you very much. Thanks for taking all my questions. Yeah, thank you. Yeah, appreciate it. Thank you. That concludes our question and answer session. I'd like to turn the conference back over to the company for any closing remarks. Listen, I wanna thank everybody for showing up today. Appreciate the support. We're excited about the journey that we're getting ready to head on and can't wait to report out next time. Thanks, everybody. Have a great day. Thank you, sir. That concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.